Literature DB >> 12223581

Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington's disease knock-in mice.

Liliana B Menalled1, Jessica D Sison, Ying Wu, Melisa Olivieri, Xiao-Jiang Li, He Li, Scott Zeitlin, Marie-Françoise Chesselet.   

Abstract

Huntington's disease (HD) is characterized by a progressive loss of neurons in the striatum and cerebral cortex and is caused by a CAG repeat expansion in the gene encoding huntingtin. Mice with the mutation inserted into their own huntingtin gene (knock-in mice) are, genetically, the best models of the human disease. Here we show for the first time that knock-in mice with 94 CAG repeats develop a robust and early motor phenotype at 2 months of age, characterized by increased rearing at night. This initial increase in repetitive movements was followed by decreased locomotion at 4 and 6 months, despite a normal life span. The decrease in striatal enkephalin mRNA that is known to occur at 4 months was not present at 2 months, when increased rearing was observed. Both the hyperactive and hypoactive phases of motor dysfunction preceded the detection of nuclear microaggregates of mutated huntingtin in striatal neurons. Nuclear microaggregates, defined as small huntingtin-positive punctas detected by light microscopy, were very rare at 4 months but became widely distributed in striatal neurons at 6 months. Nuclear inclusions did not appear until 18 months. When present, nuclear microaggregates predominated in the striosomal compartment of the striatum, providing a possible explanation for the different neuronal vulnerability of striatal compartments observed in humans. The early motor phenotype observed in the knock-in mouse is reminiscent of repetitive movements often observed in early HD and provides a novel opportunity to assess the ability of therapies to prevent the initial effects of the mutation in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12223581      PMCID: PMC6758087     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  44 in total

1.  Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice.

Authors:  H Li; S H Li; A L Cheng; L Mangiarini; G P Bates; X J Li
Journal:  Hum Mol Genet       Date:  1999-07       Impact factor: 6.150

2.  Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice.

Authors:  G J Klapstein; R S Fisher; H Zanjani; C Cepeda; E S Jokel; M F Chesselet; M S Levine
Journal:  J Neurophysiol       Date:  2001-12       Impact factor: 2.714

3.  Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity.

Authors:  H Li; S H Li; H Johnston; P F Shelbourne; X J Li
Journal:  Nat Genet       Date:  2000-08       Impact factor: 38.330

4.  Striking changes in anxiety in Huntington's disease transgenic mice.

Authors:  S E File; A Mahal; L Mangiarini; G P Bates
Journal:  Brain Res       Date:  1998-09-14       Impact factor: 3.252

5.  Huntingtin localization in brains of normal and Huntington's disease patients.

Authors:  E Sapp; C Schwarz; K Chase; P G Bhide; A B Young; J Penney; J P Vonsattel; N Aronin; M DiFiglia
Journal:  Ann Neurol       Date:  1997-10       Impact factor: 10.422

6.  Motor disorder in Huntington's disease begins as a dysfunction in error feedback control.

Authors:  M A Smith; J Brandt; R Shadmehr
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

7.  Expression of normal and mutant huntingtin in the developing brain.

Authors:  P G Bhide; M Day; E Sapp; C Schwarz; A Sheth; J Kim; A B Young; J Penney; J Golden; N Aronin; M DiFiglia
Journal:  J Neurosci       Date:  1996-09-01       Impact factor: 6.167

8.  Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion.

Authors:  J K White; W Auerbach; M P Duyao; J P Vonsattel; J F Gusella; A L Joyner; M E MacDonald
Journal:  Nat Genet       Date:  1997-12       Impact factor: 38.330

9.  Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition.

Authors:  M Kim; H S Lee; G LaForet; C McIntyre; E J Martin; P Chang; T W Kim; M Williams; P H Reddy; D Tagle; F M Boyce; L Won; A Heller; N Aronin; M DiFiglia
Journal:  J Neurosci       Date:  1999-02-01       Impact factor: 6.167

10.  Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions.

Authors:  F Saudou; S Finkbeiner; D Devys; M E Greenberg
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

View more
  69 in total

1.  A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.

Authors:  Damian M Cummings; Yasaman Alaghband; Miriam A Hickey; Prasad R Joshi; S Candice Hong; Chunni Zhu; Timothy K Ando; Véronique M André; Carlos Cepeda; Joseph B Watson; Michael S Levine
Journal:  J Neurophysiol       Date:  2011-11-09       Impact factor: 2.714

2.  Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Aaron C Rising; Jia Xu; Aaron Carlson; Vincent V Napoli; Eileen M Denovan-Wright; Ronald J Mandel
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

3.  Extensive early motor and non-motor behavioral deficits are followed by striatal neuronal loss in knock-in Huntington's disease mice.

Authors:  M A Hickey; A Kosmalska; J Enayati; R Cohen; S Zeitlin; M S Levine; M-F Chesselet
Journal:  Neuroscience       Date:  2008-08-27       Impact factor: 3.590

Review 4.  Huntington's disease: can mice lead the way to treatment?

Authors:  Zachary R Crook; David Housman
Journal:  Neuron       Date:  2011-02-10       Impact factor: 17.173

Review 5.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 6.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

Review 7.  Large Animal Models of Huntington's Disease.

Authors:  Xiao-Jiang Li; Shihua Li
Journal:  Curr Top Behav Neurosci       Date:  2015

8.  Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation.

Authors:  Delphine Charvin; Peter Vanhoutte; Christiane Pagès; Emilliana Borrelli; Emiliana Borelli; Jocelyne Caboche
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-15       Impact factor: 11.205

Review 9.  The ubiquitin-proteasome pathway in Huntington's disease.

Authors:  Steven Finkbeiner; Siddhartha Mitra
Journal:  ScientificWorldJournal       Date:  2008-04-20

Review 10.  Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms.

Authors:  Carlos Cepeda; Damian M Cummings; Véronique M André; Sandra M Holley; Michael S Levine
Journal:  ASN Neuro       Date:  2010-04-07       Impact factor: 4.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.